Company
Idorsia
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
2
Approvals since 2021
4
Originals and new uses
Phase 3 trials
16
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the DayPivotal-lookingRecruiting
Idorsia Pharmaceuticals Ltd.Industry
NCT07843329 · 344 participants (planned) · Start Oct 28, 2026 · Primary completion Nov 22, 2027
Drug: Daridorexant; Placebo · For: Insomia Disorder
Sites: Little Rock, Arkansas; Lemon Grove, California; Pomona, California · 9 sites in all
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseasePivotal-lookingRecruiting
Idorsia Pharmaceuticals Ltd.Industry
NCT07778667 · 16 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 13, 2029
Drug: Lucerastat · For: Fabry Disease
Sites: Birmingham, Alabama; Oakland, California; Gainesville, Florida · 16 sites in all
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.